VBIV: חובות מצטברים של החברה VBI Vaccines Inc

The price chart on the GURU.Markets platform demonstrates a specific debt level of 0.00. VBI Vaccines Inc. (VBIV) produces an advanced hepatitis B drug, which enables the company to command a premium price in government contracts. The business relies on unique viral structure mimicry to combat brain cancer and infections. Meanwhile, tacit preferences for insurance companies are being utilized to expand the PreHevbrio market.

Developing vaccines based on the VLP platform requires significant capital expenditures in biosafety and raw materials to combat glioblastoma and hepatitis B. The dynamics of the total debt load reflect the sum of loans and liabilities to suppliers, allowing investors to assess interest expense risk and the issuer's solvency through daily monitoring of borrowed capital on the VBI Vaccines Inc. (VBIV) chart.